IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2019.03096
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Psoriasis: IL-17A-Antikörper Garantieren Raschen Wirkeintritt

hautnah dermatologie
2017English

Secukinumab: First IL-17A Antagonist for Plaque Psoriasis

Pharmacy Today
2015English

Psoriasis and the MAITing Game: A Role for IL-17A+ Invariant TCR CD8+ T Cells in Psoriasis?

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2014English

IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A

Journal of Immunology
AllergyImmunology
2010English

The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond

Expert Review of Clinical Immunology
AllergyImmunology
2019English

Potentiation of IL-19 Expression in Airway Epithelia by IL-17A and IL-4/IL-13: Important Implications in Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2008English

Transcriptome Profiling Unveils the Role of Cholesterol in IL-17A Signaling in Psoriasis

Scientific Reports
Multidisciplinary
2016English

Mannan Induces ROS-regulated, IL-17A-dependent Psoriasis Arthritis-Like Disease in Mice

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2014English

Meta-Analysis of RNA Sequencing Datasets Reveals an Association Between TRAJ23, Psoriasis, and IL-17A

JCI insight
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy